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Abstract
Background: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop cancer despite
testing negative for the family’s pathogenic variant. These families may have additional genetic variants, which not only
may increase the susceptibility of the families’ path_BRCA1/2, but also be capable of causing cancer in the absence of
the path_BRCA1/2 variants. We aimed to identify novel genetic variants in prospectively detected breast cancer (BC) or
gynecological cancer cases tested negative for their families’ pathogenic BRCA1/2 variant (path_BRCA1 or path_BRCA2).
Methods: Women with BC or gynecological cancer who had tested negative for path_BRCA1 or path_BRCA2 variants
were included. Forty-four cancer susceptibility genes were screened for genetic variation through a targeted amplicon-
based sequencing assay. Protein- and RNA splicing-dedicated in silico analyses were performed for all variants of
unknown significance (VUS). Variants predicted as the ones most likely affecting pre-mRNA splicing were experimentally
analyzed in a minigene assay.
Results: We identified 48 women who were tested negative for their family’s path_BRCA1 (n = 13) or path_BRCA2 (n =
35) variants. Pathogenic variants in the ATM, BRCA2, MSH6 and MUTYH genes were found in 10% (5/48) of the cases, of
whom 15% (2/13) were from path_BRCA1 and 9% (3/35) from path_BRCA2 families. Out of the 26 unique VUS, 3 (12%)
were predicted to affect RNA splicing (APC c.721G > A, MAP3K1 c.764A > G and MSH2 c.815C > T). However, by using a
minigene, assay we here show that APC c.721G > A does not cause a splicing defect, similarly to what has been recently
reported for the MAP3K1 c.764A > G. The MSH2 c.815C > T was previously described as causing partial exon skipping
and it was identified in this work together with the path_BRCA2 c.9382C > T (p.R3128X).
Conclusion: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing
irrespective of which causative genetic variants have been demonstrated in their relatives.
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Background
Breast cancer (BC) is one of the most common human
malignancies, accounting for 22% of all cancers in
women worldwide [1]. A significant proportion of BC
cases can be explained by hereditary predisposition and
approximately 30% of this hereditary cancer risk is ex-
plained by the currently known high-penetrance
susceptibility genes [2–5]. Notably, carriers of patho-
genic BRCA1 or BRCA2 variants (path_BRCA1 or
path_BRCA2) have an increased risk of developing BC
(average lifetime risk of 35–85%) and ovarian cancer
(average lifetime risk 11–39%). Further, carriers of
pathogenic variants of ATM, CHEK2, PALB2, NBS1 and
RAD50 have been found to confer two- to five-fold in-
creased risk for developing BC [1, 6]. It is also known
that pathogenic variants in TP53, PTEN, STK11 and
CDH1, resulting in Li-Fraumeni syndrome, Cowden syn-
drome, Peutz–Jeghers syndrome and hereditary diffuse
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gastric cancer, respectively, are associated with a high
lifetime risk (> 40%) of BC. Moreover, pathogenic vari-
ants in RAD51 paralogs, i.e., RAD51C, confer an in-
creased risk of ovarian cancer [7]. The frequency of
pathogenic variants in BC-associated genes varies signifi-
cantly among different populations, as exemplified by
the frequently studied founder pathogenic variant
c.1100delC in CHEK2 [6].
The identification of path_BRCA1 or path_BRCA2 in
an affected BC individual enables access to evidence-
based screening for family members, and thus facilitates
the implementation of appropriate cancer prevention in
these families [1, 5, 6]. However, some women in fam-
ilies with an identified pathogenic variant will develop
cancer despite testing negative for the family’s patho-
genic variant, often denoted as phenocopies [8]. In BC
kindreds having a demonstrated path_BRCA2 variant,
the number of phenocopies is reportedly more frequent
than expected by chance [8–10]. It has been proposed
that these families may have additional genetic variants,
which not only may increase the susceptibility of the
families’ path_BRCA1/2, but also be capable of causing
cancer in the absence of the path_BRCA1/2 demon-
strated in the families [5–7].
The current practice of genetic counselling for women
who do not carry the path_BRCA1/2 variants of their
relatives is challenging since their recognition is crucial
for application of proper diagnostic and therapeutic ap-
proaches in these families. To discover additional inher-
ited disease-causing variants in path_BRCA1/2 kindreds,
we examined all prospectively detected BC or
gynecological cancer cases in these kindreds by next-
generation sequencing (NGS) using a panel of 44 cancer
susceptibility genes. All detected variants were analyzed
by RNA splicing- and protein-dedicated in silico
methods. Variants predicted as the most likely to affect
splicing were experimentally analyzed by using a cell-
based minigene splicing assay.
Methods
Study population
For more than 20 years, we (the Hereditary Cancer Bio-
bank from the Norwegian Radium Hospital, Norway;
and the Department of Genomic Medicine from the
University of Manchester, United Kingdom) have ascer-
tained BC and breast/ovarian cancer kindreds by family
history. The sisters and daughters of cancer patients
were initially subjected to follow-up by annual mam-
mography and gynecological examinations as appropri-
ate at that time, and later they were all subjected to
genetic testing [11].
Both collaborating outpatient genetic centers identified
48 women with prospective detected BC or gynecological
cancer at follow-up, who were tested negative for their
respective families’ path_BRCA1/2 variants. Clinical data
were obtained from pathology reports and clinical files.
Ethical approval for the prospective study was granted
from the Norwegian Data Inspectorate and Ethical Re-
view Board (ref 2015/2382). All examined patients had
signed an informed consent for their participation in the
study.
Targeted sequencing
Genomic DNA was isolated from peripheral blood sam-
ples and targeted sequencing was carried out using a
TrueSeq amplicon based assay v.1.5 on a MiSeq appar-
atus, as previously described [12]. The 44-gene panel
used in this work includes genes associated with cancer
predisposition as described in a prior study [12].
Sequencing data analysis
Paired-end sequence reads were aligned to the human
reference genome (build GRCh37) using the BWA-mem
algorithm (v.0.7.8-r55) [13]. The initial sequence align-
ments were converted to BAM format and subsequently
sorted and indexed with SAMtools (v.1.1) [13]. Genotyp-
ing of single nucleotide variants (SNV) and short indels
was performed by GATK’s HaplotypeCaller. Filtering of
raw genotype calls and assessment of callable regions/
loci were done according to GATK’s best practice proce-
dures, as described more detail previously [12].
Variants were annotated using ANNOVAR (version
November 2015) [14] and were queried against a range
of variant databases and protein resources (v29, Decem-
ber 2015), as previously described [12].
Validation by cycling temperature capillary
electrophoresis
The pathogenic variants identified in this study were val-
idated by cycling temperature capillary electrophoresis.
The method is based on allele separation by cooperative
melting equilibrium while cycling the temperature sur-
rounding capillaries [15]. This approach has previously
been described and extensively used to detect somatic
mutations and single nucleotide polymorphisms (SNPs)
[16–19]. The amplicon design was performed by the
variant melting profile tool (https://hyperbrowser.uio.no/
hb/?tool_id=hb_variant_melting_profiles/) [20]. Primer
sequences, PCR reaction conditions and electrophoresis
settings are described in Additional file 1.
Genetic variants nomenclature and classification
The nomenclature guidelines of the Human Genome Vari-
ation Society (HGVS) were used to describe the detected
genetic variants [21]. The recurrence of the identified vari-
ants was established by interrogating six databases (in
their latest releases as of November 2016): Evidence-based
Network for the Interpretation of Germline Mutant
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Alleles (ENIGMA), Breast Cancer Information Core Data-
base (BIC), the International Society of Gastrointestinal
Hereditary Tumors (InSiGHT) Database, the Leiden Open
Variation Database (LOVD), ClinVar, and the Human
Gene Mutation Database (HGMD).
Novel variants were considered pathogenic if either
one of the following criteria was met: a) introduced a
premature stop codon in the protein sequence (nonsense
or frameshift); b) occurred at positions + 1/+ 2 or − 1/−
2 of donor or acceptor splice sites, respectively; and c)
represented whole-exon deletions or duplications.
In silico analyses of VUS
Two types of bioinformatics methods were used to pre-
dict the impact of selected variants on RNA splicing.
First, we used MaxEntScan (MES) and SSF-like (SSFL)
to predict variant-induced alterations in 3′ and 5′ splice
site strength, as described by Houdayer et al. [22], except
that here both algorithms were interrogated by using the
integrated software tool Alamut Batch version 1.5,
(Interactive Biosoftware, http://www.interactive-biosoft-
ware.com). For prediction of variant-induced impact on
exonic splicing regulatory elements (ESR), we resorted
to ΔtESRseq- [23], ΔHZei- [24], and SPANR-based [25]
as described by Soukarieh et al. [26]. Score differences
(Δ) between variant and wild-type (WT) cases were
taken as proxies for assessing the probability of a spli-
cing defect. More precisely, we considered that a variant
mapping at a splice site was susceptible of negatively
impacting exon inclusion if ΔMES≥15% and ΔSSFL≥5%
[22], whereas an exonic variant located outside the splice
sites was considered as a probable inducer of exon skip-
ping if negative Δ scores (below the thresholds described
below) were provided by all the 3 ESR-dedicated in silico
tools. We chose the following thresholds: <− 0.5 for
ΔtESRseq-, <− 10 for ΔHZei-, and < − 0.2 for SPANR-
based scores. In addition, we evaluated the possibility of
variant-induced de novo splice sites by taking into con-
sideration local changes in MES and SSFL scores. In this
case, we considered that variants located outside the
splice sites were susceptible of creating a competing
splice site if local MES scores were equal to or greater
than those of the corresponding reference splice site for
the same exon.
In silico protein impact predictions of VUS were per-
formed with FATHMM (http://fathmm.biocompute.or-
g.uk) (v2.3), PolyPhen2-HVAR (v 2.2.2), MutationTaster
(data release Nov 2015), MutationAssessor (release 3),
SIFT (Jan 2015) and PROVEAN (v1.1 Jan 2015) using
dbNSFP v3.4.
Cell-based minigene splicing assays
In order to determine the impact of the APC c.721G > A
on RNA splicing, we performed functional assays based
on the comparative analysis of the splicing pattern of
WT and mutant reporter minigenes [27], as follows.
First, the genomic region containing APC exon 7 and at
least 150 nucleotides of the flanking introns (c.646–169
to c.729 + 247) were amplified by PCR using patient
#12470 DNA as template and primers indicated in
Additional file 2. Next, the PCR-amplified fragments
were inserted into a previously linearized pCAS2 vector
[26] to generate the pCAS2-APC exon 7 WT and
c.721G > A minigenes. All constructs were sequenced to
ensure that no unwanted mutations had been introduced
into the inserted fragments during PCR or cloning.
Then, WT and mutant minigenes were transfected in
parallel into HeLa cells grown in 12-well plates (at ~
70% confluence) using the FuGENE 6 transfection re-
agent (Roche Applied Science). Twenty-four hours later,
total RNA was extracted using the NucleoSpin RNA II
kit (Macherey Nagel) and, the minigene transcripts were
analyzed by semi-quantitative RT-PCR using the One-
Step RT-PCR kit (QIAGEN), as previously described
[26]. The sequences of the RT-PCR primers are shown
in Additional file 2. Then, RT-PCR products were sepa-
rated by electrophoresis on 2.5% agarose gel containing
EtBr and visualized by exposure to UV light under satur-
ating conditions using the Gel Doc XR image acquisition
system (Bio-Rad), followed by gel-purification and
Sanger sequencing for proper identification of the mini-
genes’ transcripts. Finally, splicing events were quanti-
tated by performing equivalent fluorescent RT-PCR
reactions followed by capillary electrophoresis on an au-
tomated sequencer (Applied Biosystems), and computa-
tional analysis by using the GeneMapper v5.0 software
(Applied Biosystems).
Results
Family history and clinical characteristics
In total, we identified 48 cases, of whom 18 BC or
gynecological cancer patients who did not carry their re-
spective families’ path_BRCA1 or path_BRCA2 variants
(n = 13 and n = 5, respectively) came from the Hereditary
Cancer Biobank from the Norwegian Radium Hospital,
while the Department of Genomic Medicine from the
University of Manchester identified a total of 30 BC pa-
tients, all non-carriers of the family’s path_BRCA2 vari-
ants (Fig. 1). The median age at first cancer diagnosis
was 53.5 years (range 31–79 years). The incidence was
higher for BC (92%), followed by ovarian cancer (4%)
and endometrial and cervical cancer (2% each) (Table 1).
Germline findings
In the 48 cases, we identified five (10%) to carry patho-
genic variants in ATM (c.468G > A, p.Trp156Ter and
c.9139C > T, p.Arg3047Ter), BRCA2 (c.9382C > T,
p.Arg3128Ter), MSH6 (c.2864delC, p.Thr955fs) and
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MUTYH (c.1178G > A, p.Gly393Asp). Among these five
cases, 2/13 were identified in non-carriers of the family’s
path_BRCA1 variant and in 3/35 non-carriers of the
family’s path_BRCA2 variant (Fig. 1). Disease type, famil-
ial path_BRCA1/2 and pathogenic variants found in this
study are shown in detail in Table 1.
Interestingly, one case with a familial path_BRCA2
(c.6591_6592delTG) was found to carry another patho-
genic variant in the same gene (BRCA2 c.9382C > T,
p.Arg3128Ter), which causes a premature stop in the
codon 3128 and is known to be a high risk pathogenic
variant (Table 1).
The pathogenic variants in BC-related genes (2 in
ATM and 1 in BRCA2) were found in 3 women with BC
or ovarian cancer, while the MSH6 and the heterozygous
MUTYH p.Gly393Asp pathogenic variant was found in a
woman with endometrial cancer at 57 years and BC
diagnosis at 56 years, respectively (Table 1).
Validation of the cancer gene panel output
The presence of the five pathogenic variants detected by
targeted NGS was confirmed by cycling temperature ca-
pillary electrophoresis, showing 100% correspondence
between both methods.
Variants of unknown significance (VUS) and predicted
protein alterations
In total, we found 26 unique VUS in 30 out of 48 pa-
tients (63%). Common polymorphisms (with an allele
frequency ≥ 1% in the general population according to
the ExAC database) and benign variants classified ac-
cording to either ClinVar or the American College of
Medical Genetics and Genomics (ACMG) guidelines
were excluded from further analyses [41, 58].
The VUS were detected in 17 genes, namely: AXIN2,
RAD51B (in 4 patients each), MAP3K1 (in 3 patients),
APC, ATM, MSH2, NBN, POLE (in 2 patients each),
BRCA1, CDH1, CDX2, DVL2, MRE11A, MUTYH,
NOTCH3, PTEN and RAD51D (in 1 patient each)
(Table 2). The minor allele frequencies (MAF) of these
variants in public databases were very low or no fre-
quency data have been reported (Table 2).
The VUS were furthermore analyzed by using 6 in
silico protein prediction tools with different underlying
algorithms (Fig. 2). The MRE11A c.1139G > A and the
MUTYH c.881G > A variants were suggested to have a
potentially damaging effect on protein level by all six
predictions programs. For the variants in the MSH2,
NBN, POLE and BRCA1 genes (MSH2 c.815C > T, NBN
c.283G > A, POLE c.2459 T > C and BRCA1 c.1927A > G,
Fig. 1 Flow chart showing the study population selection from the Hereditary Cancer Biobank from the Norwegian Radium Hospital, Norway. It contains
ascertained BC and breast/ovarian cancer kindreds by family history that were all subjected to genetic testing. The identification of phenocopies involved
48 women with prospective detected BC or gynecological cancer at follow-up, who were tested negative for their respective families’ path_BRCA1/2
variants. Among these cases, 13 were identified in non-carriers of the family’s path_BRCA1 variant and in 35 non-carriers of the family’s path_BRCA2 variant
(n= 30 from the Department of Genomic Medicine from the University of Manchester). Pathogenic variants were identified in 5/48 (10%) BC or
gynecological cancer cases
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Table 1 Summary of the 48 prospective BC or gynecological cancer patients included in the study
Patient_ID Institution Familial path_
BRCA1 or path_BRCA2
variantFamilial path_BRCA1
or path_BRCA2 variant
ICD9
diagnosis
(age)
Pathogenic variant
identified in the
current study
17,161 HCBNRH BRCA2 c.5217_5223delTTTAAGT
(p.Tyr1739Terfs)BRCA2 c.5217_5223delTTTAAGT
(p.Tyr1739Terfs)
OC (67) ATM c.468G > A
(p.Trp156Ter)*ATM c.468G >
A (p.Trp156Ter)*
6475 HCBNRH BRCA1 c.1011dupA (p.Val340Glyfs)BRCA1
c.1011dupA (p.Val340Glyfs)
BC (52) ATM c.9139C > T
(p.Arg3047Ter)ATM
c.9139C > T (p.Arg3047Ter)
13,141 HCBNRH BRCA1 c.1072delC (p.Leu358Cysfs)BRCA1
c.1072delC (p.Leu358Cysfs)
EC (57) MSH6 c.2864delC
(p.Thr955fs)*MSH6
c.2864delC (p.Thr955fs)*
1873 HCBNRH BRCA1 c.1556delA (p.Lys519Argfs)BRCA1
c.1556delA (p.Lys519Argfs)
MTHM (56), BC (70) Not
5378 HCBNRH BRCA1 c.697_698delGT (p.Val233Asnfs)BRCA1
c.697_698delGT
(p.Val233Asnfs)
BC (52) Not
5180 HCBNRH BRCA1 c.5194-2A > CBRCA1 c.5194-2A > C BC (39) Not
22 HCBNRH BRCA2 c.3847_3848delGT (p.Val1283Lysfs)BRCA2
c.3847_3848delGT
(p.Val1283Lysfs)
BC (63) Not
243 HCBNRH BRCA2 c.3847_3848delGT (p.Val1283Lysfs)BRCA2
c.3847_3848delGT
(p.Val1283Lysfs)
CVC (41) Not
5348 HCBNRH BRCA1 c.1556delA (p.Lys519Argfs)BRCA1
c.1556delA (p.Lys519Argfs)
BC (68) Not
6031 HCBNRH BRCA1 c.1556delA (p.Lys519Argfs)BRCA1
c.1556delA (p.Lys519Argfs)
BC (66) Not
6032 HCBNRH BRCA1 c.3228_3229delAG (p.Gly1077Alafs)BRCA1
c.3228_3229delAG
(p.Gly1077Alafs)
OC (55) Not
6207 HCBNRH BRCA1 c.697_698delGT (p.Val233Asnfs)BRCA1
c.697_698delGT
(p.Val233Asnfs)
BC (47) Not
8085 HCBNRH BRCA1 c.3228_3229delAG (p.Gly1077Alafs)BRCA1
c.3228_3229delAG (p.Gly1077Alafs)
BC (55), CC (66) Not
11,717 HCBNRH BRCA1 c.1556delA (p.Lys519Argfs)BRCA1
c.1556delA
(p.Lys519Argfs)
BC(42,57) Not
12,470 HCBNRH BRCA1 c.3178G > T (p.Glu1060Ter) BC (39) Not
13,023 HCBNRH BRCA2 c.5217_5223delTTTAAGT
(p.Tyr1739Terfs)
BC (59) Not
15,529 HCBNRH BRCA2 c.4821_4823delTGAins BC (48) Not
22,325 HCBNRH BRCA1 c.5047G > T
(p.Glu1683Ter)
BC (45) Not
1,100,948 UM BRCA2 c.6591_6592delTG
(p.Glu2198Asnfs)
BC (44) BRCA2 c.9382C > T
(p.Arg3128Ter)
12,010,643 UM BRCA2 c.7360delA
(p.Ile2454Phefs)
BC (56) MUTYH c.1178G > A
(p.Gly393Asp)
75,443 UM BRCA2 c.5909C > A
(p.Ser1970Ter)
BC (55) Not
88,295 UM BRCA2 c.7977-1G > C BC (44) Not
64,949 UM BRCA2 c.5909C > A
(p.Ser1970Ter)
BC (55) Not
67,723 UM BC (46) Not
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five out of six predictions suggested a potentially dam-
aging effect (Fig. 2).
Discrepancies in protein-related predictions were even
more pronounced for the variants in APC, AXIN2,
RAD51B, DVL2, RAD51D, CDH1 and MSH2 c.2164G >
A. In contrast, none of the six prediction tools showed
deleterious effects for the detected variants in the
AXIN2, ATM, RAD51B and MAP3K1 genes (AXIN2
Table 1 Summary of the 48 prospective BC or gynecological cancer patients included in the study (Continued)
Patient_ID Institution Familial path_
BRCA1 or path_BRCA2
variantFamilial path_BRCA1
or path_BRCA2 variant
ICD9
diagnosis
(age)
Pathogenic variant
identified in the
current study
BRCA2 c.4866delA
p.(Arg1622Serfs*14)
84,510 UM BRCA2 c.5946delT
(p.Ser1982Argfs)
BC (67) Not
13,007,862 UM BRCA2 c.5909C > A
(p.Ser1970Ter)
BC (31) Not
9,009,462 UM BRCA2 c.6535_6536insA
(p.Val2179Aspfs)
BC (67) Not
900,178 UM BRCA2 c.1889delC
(p.Thr630Asnfs)
BC (49,77) Not
10,005,829 UM BRCA2 c.9541_9554del
p.(Met318CysfsTer13)
BC (38) Not
10,007,016 UM BRCA2 c.632-1G > A BC (51) Not
10,003,959 UM BRCA2 c.6275_6276delTT
(p.Leu2092Profs)
BC (55) Not
12,852 UM BRCA2 c.1929delG
(p.Arg645Glufs)
BC (56) Not
12,001,161 UM BRCA2 c.7958 T > C
(p.Leu2653Pro)
BC (67) Not
13,017,067 UM BRCA2 c.755_758delACAG
(p.Asp252Valfs)
BC (74) Not
688 UM BRCA2 c.1929delG
(p.Arg645Glufs)
BC (32) Not
40,540 UM BRCA2 c.8535_8538delAGAG
p.(Glu2846LysfsTer16)
BC (69) Not
9,001,644 UM BRCA2 c.4965C > G
(p.Tyr1655Ter)
BC (39, 45) Not
89,205 UM BRCA2 c.5946delT
(p.Ser1982Argfs)
BC (77) Not
10,002,068 UM BRCA2 del exons 14–16 BC (37) Not
10,004,590 UM BRCA2 c.2672dupT BC (67,67) Not
40,286 UM BRCA2 c.7069_7070delCT
p.(Leu2357ValfsTer2)
BC (36,53) Not
76,618 UM BRCA2 c.4478_4481delAAAG
(p.Glu1493Valfs)
BC (51) Not
12,015,576 UM BRCA2 c.9382C > T (p.Arg3128Ter) BC (45) Not
61,420 UM BRCA2 c.5350_5351delAA p.(Asn1784HisfsTer2) BC (59) Not
960,579 UM BRCA2 c.2808_2811del4 (p.Ala938Profs) BC (39) Not
14,965 UM BRCA2 c.5682C > G p.(Tyr1894Ter) BC (59) Not
20,468 UM BRCA2 c.6275_6276delTT (p.Leu2092Profs) BC (38) Not
56,193 UM BRCA2 c.7884dupA (p.Trp2629Metfs) BC (79) Not
HCBNRH Hereditary Cancer Biobank from the Norwegian Radium Hospital (Norway), UM University of Manchester (United Kingdom), ICD9 diagnosis International
Classification of Diseases, 9th Revision, OC Ovary cancer, BC Breast cancer, EC Endometrial cancer, MTHM Malignant neoplasm of thymus, heart, and mediastinum,
CC Colon cancer, CVC Cervical cancer, *Considered pathogenic based in its nature (nonsense and frameshift), VUS Variants of unknown significance, NM for ATM
NM_000051, BRCA1 NM_007294.3, BRCA2 NM_000059.3, MSH6 NM_001281492, MUTYH NM_012222
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c.2272G > A, ATM c.2689 T > A, RAD51B c.539A > G
and c.1063G > A and MAP3K1 c.764A > G) (Fig. 2).
Splicing-dedicated in silico analysis and minigene splicing
assays
Out of the 26 unique VUS, two (APC c.721G > A and
MAP3K1 c.764A > G) were bioinformatically predicted
as the most likely to affect RNA splicing, either by po-
tentially creating a new splice site or by altering putative
exonic splicing regulatory elements, respectively (Table
2). Given that RNA data was not available for APC
c.721G > A, we set out to experimentally evaluate the
impact on RNA splicing produced by this variant, by
performing a cell-based minigene splicing assay. As
shown in Fig. 3, we observed that c.721G > A did not
affect the splicing pattern of APC exon 7 in our system.
These results are reminiscent of those recently obtained
for MAP3K1 c.764A > G by using a similar splicing
assay, in which the variant did not cause an alteration in
the minigene’s splicing pattern (Dominguez-Valentin et
al. under submission). It would be important in both
cases to validate the minigene results by analyzing RNA
from the variant carriers/patients as compared to those
from healthy controls. However, we do not have such
material in our biobank.
To our knowledge, the only other VUS from our
list for which RNA data is available is MSH2
c.815C > T (p.Ala272Val). Previous results from differ-
ent minigene assays revealed that, albeit located out-
side the splice sites, MSH2 c.815C > T induces partial
skipping of exon 5 [28]. These results agree, at least
in part, with those obtained by analyzing RNA from a
LS patient carrying this same variant [29]. Indeed, the
latter study revealed aberrantly spliced MSH2 tran-
scripts associated with the presence of c.815C > T, but
where the severity of the splicing defect was not ad-
dressed at the time. Of note, here we identified
MSH2 c.815C > T together with another VUS (DVL2
c.596 T > C) and a path_BRCA2 c.9382C > T (different
from the familial path_BRCA2) in a patient diagnosed
with ductal carcinoma at 44 years of age (Patient
1,100,948) (Table 1).
Fig. 2 Protein-related in silico data obtained for the VUS identified in the study
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Discussion
Among prospectively detected BC or gynecological can-
cer phenocopies in the path_BRCA1/2 families, we
found that 4/48 have pathogenic variants in high-
penetrance cancer genes: two BC- and one CRC-
associated gene (ATM, BRCA2 and MSH6, respectively).
Our findings are in line with a previous study, which de-
tected a likely pathogenic variant in a gene other than
BRCA1/2 in a BC patient, i.e. MSH6 c.3848_3862del
(p.(Ile1283_Tyr1287del) [30]. In addition, we found the
MUTYH c.1178G > A (p.Gly393Asp) variant in a BC
case, which is one of the most common path_MUTYH
variants. Pathogenic MUTYH variants may cause a re-
cessively inherited colon cancer syndrome. Whether or
not individuals who are heterozygous for MUTYH muta-
tions may be at risk for cancer is debated [31]. Among
the five cases found to carry pathogenic variants, 2/13
were identified from families with path_BRCA1 and 3/
35 with path_BRCA2 variants.
Our results are in concordance with the recently pub-
lished NGS panel studies, which have demonstrated that
besides high-risk genes, like BRCA1/2 and MMR genes,
other genes may also contribute to familial cancer pre-
disposition, thus providing a broader picture on the gen-
etic heterogeneity of cancer syndromes [25, 32, 33]. In
this regard, a molecular diagnosis yield of approximately
9% to identify a pathogenic or likely pathogenic variant
in BC has been reported, and with yields of 13% in ovar-
ian and 15% in colon/stomach cancer cases [25]. On the
other hand, family history is currently used to identify
high risk patients. However, the use of family history
fails to identify women without close female relatives
who are carriers of pathogenic variants [9].
Despite the potential of NGS to identify genetic causes
among families that tested negative for pathogenic
variants in high-risk genes using traditional methods
[25, 32, 33], a high number of VUS are also detected and
constitute a major challenge in oncogenetics [34]. In this
study, we subjected 26 VUS to RNA splicing and protein
in silico evaluations, and the bioinformatics predictions
indicated that two VUS (APC c.721G > A and MAP3K1
c.764A > G) were likely to affect RNA splicing. Our
a
b d
c
Fig. 3 Analysis of the impact on RNA splicing of APC c.721G>A by using a cell-based minigene splicing assay. a Structure of pCAS2-APC.ex7 minigene used
in the assay. The bent arrow indicates the CMV promoter, boxes represent exons, lines in between indicate introns, and arrows below the exons represent
primers used in RT-PCR reactions. The WT and c.721G>A minigenes were generated by inserting a genomic fragment containing the exon of interest and
flanking intronic sequences into the intron of pCAS2, as described under Materials and Methods. b Analysis of the splicing pattern of pCAS2-APC.ex7 WT and
c.721G>A minigenes. The two constructs were introduced into HeLa cells and the minigenes’ transcripts were analyzed by RT-PCR 24 h post-transfection.
The image shows the results of a representative experiment in which the RT-PCR products were separated on a 2.5% agarose gel stained with EtBr and
visualized by exposure to ultraviolet light. M, 100 bp DNA ladder (New England Biolabs). c Quantification of splicing events observed in the minigene splicing
assay. The relative levels of exon inclusion indicated under the gel are based on RT-PCR experiments equivalent to those shown in B but performed with a
fluorescent forward primer and then separated on an automated sequencer under denaturing conditions. Quantification results were obtained by using the
GeneMapper v5.0 software (Applied Biosystems) and correspond to the average of two independent fluorescent-RT-PCR experiments. d Representative
fluorescent RT-PCR experiment. The panel shows superposed peaks corresponding to the WT and mutant products (in blue and red, respectively),
as indicated
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results from minigene splicing assays suggest, however,
that this is not the case. Complementary analysis of
patients’ RNA will be important to verify the impact on
splicing of these variants in vivo. Of note, none of the
six protein in silico prediction tools showed a deleterious
effect for the MAP3K1 c.764A > G missense variant and
inconsistences were found for the APC c.721G > A
variant.
Bioinformatics prediction tools are widely used to aid
the biological and clinical interpretation of sequence var-
iants, although it is well recognized that they have their
limitations. Co-segregation studies for further evaluation
will be key for understanding whether some of the VUS
detected in this work may have a causal effect. Some of
the VUS may in the future be reclassified as deleterious
or benign, but in the meantime, they cannot be used to
make clinical decisions [30].
A polygenic model involving a combination of mul-
tiple genomic risk factors, including the effect of low- or
moderate- penetrance susceptibility alleles may explain
the increased BC risk in women who tested negative for
family’s path_BRCA1/2 variants [5]. In addition, hetero-
zygous whole gene deletions (WGD) and intragenic
microdeletions have been reported to account for a sig-
nificant proportion of pathogenic variants underlying
cancer predisposition syndromes, although WGD were
not a common mechanism in any of the three high-risk
BC genes, BRCA1, BRCA2 and TP53 [35].
The clinical utility of gene panels such as the one used
in this study is not yet fully established and the appro-
priate routes for clinical deployment of such tests re-
main under discussion [36]. So far, the large patient
datasets generated by NGS panels may be used to ex-
plore the specific penetrance of the genes included in
these panels, and to assess the performance and implica-
tions of the use of NGS in clinical diagnostics [34].
Conclusions
In kindreds carrying path_BRCA1/2 variants, testing
only for the already known path_BRCA1/2 variants in
the family may not be sufficient to exclude increased risk
neither for BC nor for ovarian cancer or other cancers
in the healthy female relatives. Our findings suggest that
all women in BC or breast/ovarian cancer kindreds
would benefit from being offered genetic testing irre-
spective of which causative genetic variants have been
demonstrated in their relatives. In addition, we found a
number of VUS in genes other than BRCA1/2 i.e.
AXIN2, APC, DVL2, MAP3K1, RAD51B, NBN, POLE,
CDH1, CDX2, MRE11A, MUTYH, NOTCH3, PTEN and
RAD51D. All these may be suspected of being associated
with cancer in the families studied and may be consid-
ered as candidates for being included in future gene
panel testing to better understand why some families
present aggregation of cancer cases.
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